NLRP3 Protein Inhibitors Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsigh
"NLRP3 Protein Inhibitors Clinical Trials"
NLRP3 protein inhibitors companies are Halia Therapeutics, Ventus Therapeutics, EpicentRx, Zydus Lifesciences Limited, Monte Rosa Therapeutics, Inflammasome Therapeutics, Ventyx Biosciences, Biolexis Therapeutics, Halia Therapeutics, Olatec Therapeutics, Secarna Pharmaceuticals, Novo Nordisk, NodThera, and others.
(Albany, USA) DelveInsight's 'NLRP3 Protein Inhibitors Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NLRP3 protein inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the NLRP3 protein inhibitors pipeline domain.
The potential for NLRP3 inhibitors extends beyond autoimmune and inflammatory diseases. Ongoing research suggests they may also be effective in treating neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis, as well as metabolic conditions like gout and non-alcoholic steatohepatitis (NASH). This broad range of applications is driving market interest.
The NLRP3 protein inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage NLRP3 protein inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the NLRP3 protein inhibitors clinical trial landscape.
Key Takeaways from the NLRP3 Protein Inhibitors Pipeline Report
DelveInsight's NLRP3 protein inhibitors pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline NLRP3 protein inhibitors.
Key NLRP3 protein inhibitors companies such as Halia Therapeutics, Ventus Therapeutics, EpicentRx, Zydus Lifesciences Limited, Monte Rosa Therapeutics, Inflammasome Therapeutics, Ventyx Biosciences, Biolexis Therapeutics, Halia Therapeutics, Olatec Therapeutics, Secarna Pharmaceuticals, Novo Nordisk, NodThera, and others are evaluating new NLRP3 protein inhibitors drugs to improve the treatment landscape.
Promising pipeline NLRP3 protein inhibitors such as HT6184, VENT 02, Nibrozetone, ZYIL1, MRT-8102, Kamuvudine-9, VTX 3232, NLRP3 inflammasome inhibitor, Dapansutrile, NNC6022-0001, NLRP3 Research Program, NT 0796, and others are under different phases of NLRP3 protein inhibitors clinical trials.
In August 2024, Halia Therapeutics and Biolexis Therapeutics announced an ongoing collaboration that successfully identified a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation by leveraging Biolexis' MolecuLern™ AI-enabled approach. This milestone represents a significant advancement in developing treatments for neuroinflammatory disorders, including Parkinson's disease and other neurodegenerative conditions.
In June 2024, NodThera announced positive data from its Phase Ib/IIa cardiovascular risk study in inflamed obese subjects, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory, cardiovascular and metabolic risk parameters.
In May 2024, Novo Nordisk successfully dosed the first participant in a Phase I clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor licensed by Novo Nordisk in September 2022.
In April 2024, Ventus Therapeutics announced results from its Phase I clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor. The Phase I trial evaluated the pharmacodynamics, pharmacokinetics, safety, and tolerability of VENT-02 across a broad range of single and multiple ascending doses in adult healthy volunteers.
In March 2024, Parkinson's UK announced the investment of GBP 2.1 million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation and protect brain cells in Parkinson's.
NLRP3 Protein Inhibitors Overview
NOD-like receptor family pyrin domain-containing 3 (NLRP3) protein is a key component of the innate immune system, playing a crucial role in the activation of the inflammasome. The NLRP3 inflammasome is responsible for the maturation and release of pro-inflammatory cytokines such as IL-1β and IL-18. This process is essential for host defense against pathogens but can lead to chronic inflammation when dysregulated. Overactivation of the NLRP3 inflammasome is implicated in a wide range of diseases, including autoimmune disorders, metabolic syndromes, neurodegenerative diseases, and certain cancers. Thus, targeting NLRP3 with specific inhibitors has become a promising strategy for treating these inflammatory conditions.
NLRP3 protein inhibitors work by either directly blocking the NLRP3 protein or interfering with its activation pathway, thereby preventing the assembly of the inflammasome and subsequent cytokine release. These inhibitors offer a novel therapeutic approach by addressing the root cause of inflammation rather than merely managing its symptoms. Several NLRP3 inhibitors are currently under development, with some already in clinical trials for diseases like gout, rheumatoid arthritis, and type 2 diabetes. Their ability to modulate the inflammatory response makes them a potential game-changer in the treatment of chronic inflammatory diseases, offering hope for more effective and targeted therapies.
A snapshot of the Pipeline NLRP3 Protein Inhibitors Drugs mentioned in the report:
Nibrozetone: EpicentRx
ZYIL 1: Zydus Cadila
HT6184: Halia Therapeutics
VTX 3232: Ventyx Biosciences
VENT 02: Ventus Therapeutics
NNC6022-0001: Novo Nordisk
Kamuvudine-9: Inflammasome Therapeutics
MRT-8102: Monte Rosa Therapeutics
Learn more about the emerging NLRP3 protein inhibitors @ NLRP3 Protein Inhibitors Medication and FDA approval
NLRP3 Protein Inhibitors Therapeutics Assessment
The NLRP3 protein inhibitors pipeline report proffers an integral view of the emerging NLRP3 protein inhibitors segmented by stage, product type, molecule type, and route of administration.
Scope of the NLRP3 Protein Inhibitors Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Intravaginal, Oral, Parenteral, Subcutaneous, Topical
Therapeutics Assessment By Molecule Type: Vaccines, Monoclonal antibody, Peptides, Polymer, Small molecule
Key NLRP3 Protein Inhibitors Companies: Monte Rosa Therapeutics (NASDAQ: GLUE), Ventyx Biosciences (NASDAQ: VTYX), Zydus Lifesciences Limited (BSE: 532321, NSE: ZYDUSLIFE), and Novo Nordisk (NYSE: NVO, OMX: NOVO-B), Halia Therapeutics, Ventus Therapeutics, EpicentRx, Inflammasome Therapeutics, Biolexis Therapeutics, Olatec Therapeutics, Secarna Pharmaceuticals, and NodThera, and others
Key NLRP3 Protein Inhibitors Pipeline Therapies: HT6184, VENT 02, Nibrozetone, ZYIL1, MRT-8102, Kamuvudine-9, VTX 3232, NLRP3 inflammasome inhibitor, Dapansutrile, NNC6022-0001, NLRP3 Research Program, NT 0796, and others
Dive deep into rich insights for new NLRP3 protein inhibitors, visit @ NLRP3 Protein Inhibitors Therapies and Drugs
Table of Contents
1. NLRP3 Protein Inhibitors Pipeline Report Introduction
2. NLRP3 Protein Inhibitors Pipeline Report Executive Summary
3. NLRP3 Protein Inhibitors Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. NLRP3 Protein Inhibitors Clinical Trial Therapeutics
6. NLRP3 Protein Inhibitors Pipeline: Late-Stage Products (Pre-registration)
7. NLRP3 Protein Inhibitors Pipeline: Late-Stage Products (Phase III)
8. NLRP3 Protein Inhibitors Pipeline: Mid-Stage Products (Phase II)
9. NLRP3 Protein Inhibitors Pipeline: Early-Stage Products (Phase I)
10. NLRP3 Protein Inhibitors Pipeline Therapeutics Assessment
11. Inactive Products in the NLRP3 Protein Inhibitors Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the NLRP3 Protein Inhibitors Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
3 days ago
- Winnipeg Free Press
Sponsored Content Preparing for the future: The importance of estate planning
Canada is currently undergoing the largest intergenerational wealth transfer in history, but more than half of us aren't ready. A recent study by IG Wealth Management (IG) uncovered that 54 per cent of Canadians don't have an estate plan, leaving them and their loved ones unprepared for carrying out final wishes. A well-crafted estate plan offers peace of mind by preparing for potential incapacity later in life and ensuring that your assets are distributed according to your wishes. It can also help reduce any tax burden on your beneficiaries. Key components to include in an estate plan include a will, healthcare directive, naming beneficiaries, purchasing life insurance and designating a power of attorney. 'It's understandable that Canadians want to avoid thinking and speaking about death, but having these difficult conversations now and ensuring that a comprehensive plan is in place will make it easier in the future, both for yourself and your loved ones,' said Christine Van Cauwenberghe, Head of Financial Planning at IG Wealth Management. Understanding an estate plan Canadians have noted that the main reason why they haven't prepared an estate plan is because they don't think they have enough wealth to make having one worthwhile. They're also unfamiliar with key aspects related to estate planning, with approximately half saying they're not knowledgeable about the tax considerations associated with passing along an estate, the benefits of having life insurance and the consequences of not having a will or power of attorney. 'It's concerning that so many Canadians are unfamiliar with key components that make up an estate plan,' said Ms. Van Cauwenberghe. 'Take, for instance, the lack of knowledge around taxation. The reality is that passing down assets can often result in a significant tax burden and Canadians should be well-versed on the strategies to help offset these costs.' Preparing for cognitive decline An estate plan is also needed in case of cognitive decline. Conditions like Alzheimer's disease can impact one's ability to make decisions around their wealth and assets. There can also often be significant costs related to living with cognitive decline. Just one quarter have planned for any possible expenses related to cognitive decline. In addition, only one-third per cent have made plans for what will happen to their assets and just under 40 per cent have made plans for who will manage their finances. 'Cognitive decline can happen to anyone at any time, so it's a good idea for Canadians to seek out the assistance of a financial advisor who can help them build a thoughtfully crafted estate plan that takes this into account,' reinforced Ms. Van Cauwenberghe. Start with a plan For more on how to build an estate plan that meets your needs, listen to a special edition of IG Wealth Management's The Living Market podcast hosted by Aurèle Courcelles, Vice-President, Tax & Estate Planning at IG Wealth Management with Dan Britton, Assistant Vice-President, Tax & Estate Planning at IG Wealth Management: The Living Market Podcast | IG Wealth Management
Toronto Star
01-06-2025
- Toronto Star
Gardiner, Don Valley Parkway to be shut down on Sunday for a bike ride. What you need to know
If you are planning on being in Toronto today, you may want to plan alternative routes as the downtown core, Don Valley Parkway and Gardiner Expressway will see disruptions. The DVP from the Gardiner Expressway to York Mills Road and the Gardiner from the South Kingsway to the DVP will be closed for the Bike for Brain Health. Participants will take over Toronto's highways from 2 a.m. until 4 p.m., riding traffic free, while raising awareness and donations for Alzheimer's research. ARTICLE CONTINUES BELOW Gta 'An opportunity to say thank you': UHN's first large-scale fundraising walk celebrates health care and innovation We Walk UHNited's Saturday event advocates for Canadian health care and celebrated the patients helped by the hospital network. Gta 'An opportunity to say thank you': UHN's first large-scale fundraising walk celebrates health care and innovation We Walk UHNited's Saturday event advocates for Canadian health care and celebrated the patients helped by the hospital network. Roads surrounding the Exhibition Place such as Saskatchewan Road, British Columbia Road, Princes Boulevard, Quebec Street, PEI Crescent and Dufferin Street between Springhurst Avenue and Saskatchewan Road will also be closed. While public transportation is recommended, the event has disrupted the 329 Dufferin night buses Sunday morning. The route will not enter the Canadian National Exhibition grounds and will stop at the Dufferin Gate Loop. The TTC warned riders that the event may also cause delays to the 91 Woodbine and 95 York Mills routes until 4 p.m. Adding to the weekend's disruptions, the first-ever We Walk UHNited fundraiser took place on Saturday, with 2K and 5K walks in support of the UHN Foundation leading to multiple downtown street closures through the morning and early afternoon. With files from Kristjan Lautens
Globe and Mail
30-05-2025
- Globe and Mail
Theralase(R) 1Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (" Theralase®" or the " Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited interim consolidated 1Q2025 financial statements (" Financial Statements"). Theralase® will be hosting a conference call on Monday June 9 th, 2025 at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending March 31 st, 2025. Questions are welcome; however, to ensure we have time to review and properly address them during the call, please send them in advance to mperraton@ An archived version will be available on the website following the conference call. 1 Other represents foreign exchange, interest accretion on lease liabilities and / or interest income To view an enhanced version of this graphic, please visit: Financial Highlights For the three-month period ended March 31, 2025: Total revenue was $91,190, compared to $175,554 in Q1 2024, a 48% year-over-year decrease. Cost of sales was $77,896 (85% of revenue), resulting in a gross margin of $13,294 (15% of revenue), down from $62,114 (35% of revenue) in Q1 2024. Selling expenses were $68,143, essentially flat compared to $67,552 in the prior year. Administrative expenses rose to $555,074 from $511,495, a 9% increase driven primarily by professional fees and stock-based compensation. Research and development expenses were $877,670, up from $756,380, reflecting increased activity to support Study II progress. Net loss for the period was $1,471,250, compared to $1,266,711 in Q1 2024. This includes $220,538 in non-cash charges such as amortization and stock-based compensation. Operational Highlights Private Placements On March 10, 2025, the Company closed a non-brokered private placement of 1,034,002 units at $0.30 per unit for gross proceeds of $310,201. Each unit consisted of one common share and one non-transferable common share purchase warrant exercisable at $0.45 for five years. Net proceeds were $304,633, after transaction costs. On April 22, 2025, the Company completed another non-brokered private placement, issuing 1,995,829 units at $0.21 per unit for gross proceeds of $419,124. Each unit included one common share and one non-transferable common share purchase warrant exercisable at $0.32 for five years. The Company has raised approximately $CAN 6.3 million over the last 2 years through non-brokered private placements in support of its research and development programs. It is currently investigating the use of a full-service investment bank in the United States to advise on potential financings and US listing opportunities. Information on any future financings will be released once available in accordance with applicable securities laws. Herpes Simplex Virus ("HSV") Treatment Program Theralase® continues preclinical development of its HSV treatment using non-light activated and light-activated small molecules. The Company is actively working on in-vitro, and in the near future, in-vivo HSV preclinical models to finalize a formulation for optimal dermal penetration to increase patient safety and efficacy. Good Laboratory Practice (" GLP") toxicology studies will commence once a formulation has been finalized. Additional details will be announced as strategic objectives are achieved. Phase II Bladder Cancer Study Update ("Study II") 82 patients have been treated with the Study Procedure, representing approximately 91% of the total targeted enrollment of 90 evaluable patients. 69 patients have completed their 90-day assessment and are considered evaluable for interim efficacy analysis. 13 additional patients are pending their 90-day assessment and will be included in future efficacy updates once evaluations are complete. Interim Clinical Results For the primary endpoint of Study II (Complete Response (" CR") at any point in time) 62% of patients provided the Study Procedure (Study Drug activated by the Study Device) demonstrated a CR. Including patients, who demonstrated an Indeterminate Response (" IR") (negative cystoscopy and positive or suspicious urine cytology), the Total Response ("TR") increases to 70%. This represents that approximately 2 out of 3 BCG-Unresponsive NMIBC CIS patients treated with Theralase®'s unique Study Procedure are demonstrating complete destruction of their bladder cancer. For the secondary endpoint of Study II (duration of CR) 42% of treated patients who achieved a CR, maintained their CR response for at least 12 months (450 days from date of Study Procedure). For the tertiary endpoint of Study II (safety of Study Procedure) 100% (69/69) experienced no Serious Adverse Events (" SAEs") directly related to the Study Drug or Study Device. Outside of the defined endpoints of Study II, Theralase® has demonstrated a duration of CR at extended time points of 23% at 2 years, 21% at 3 years and 2% at 7 years. Note: Not all patients have been assessed at these extended time points. As more clinical data is collected, the duration of CR at 2, 3 and 7 years may increase. Theralase® is on track to complete enrollment in Study II by the summer of 2025. This will allow the Company to report on 75 patients who have completed Study II in December 2025 and to report on all 90 patients by September 2026. Upon follow-up of all patients, the Company plans to submit a New Drug Application ("NDA") to Health Canada and the FDA in 4Q2026, with a decision expected by the respective regulatory authorities on a marketing approval in 2027. As Theralase® completes enrollment in Study II, it is actively searching for commercialization partners for international marketing and sales of Ruvidar®. To this end, Theralase® is in various stages of initial and advanced discussions with international pharmaceutical companies for various geographical territories concerning: Licensing of the light-activated Ruvidar® for BCG-Unresponsive NMIBC CIS Collaborative research focused on investigating light-activated Ruvidar® in the treatment of NMIBC Collaborative research focused on combining Ruvidar® with other FDA approved drugs In recent discussions with the FDA, the Company has decided that since Study II is 91% complete, the best course of action is not to pursue Break Through Designation, but to complete Study II and submit the clinical data to the FDA in a formal NDA. At the end of the meeting, the FDA made a comment that they were impressed that the interim clinical data obtained to date was able to be achieved with only one clinical treatment, in the majority of cases. Ruvidar® has demonstrated 10 years of shelf life, strongly supporting the stability of the molecule and the ability of clinics to store the small molecule for extended periods of time. Additional Oncology Targets Theralase® has combined Ruvidar® with transferrin (human glycoprotein) to form Rutherrin®. Rutherrin® is a strong candidate for the systemic treatment of recurrent, deep seated and/or progressive cancers. Due to the limitations of using laser light to activate Rutherrin® in deep oncological targets, Theralase® plans to activate Rutherrin® with radiation therapy to increase the "tumour's damage zone" and the effectiveness of Theralase®'s small molecule beyond the reach of light in the body. Rutherrin®, if clinically proven, will be able to "hunt" and "localize" into cancer cells and when activated by radiation "destroy" them; wherever, they may reside in the body. The Company expects to complete Good Laboratory Practice toxicology analysis in 4Q2025 to allow commencement of a Phase 0/I/II adaptive clinical study in 1Q2026 for the following indications: 1) Glio Blastoma Multiforme (" GBM") Brain Cancer Treatment 2) Non-Small Cell Lung Cancer (" NSCLC") Treatment 3) Pancreatic Cancer 4) Colorectal Cancer 5) Muscle Invasive Bladder Cancer (" MIBC") Treatment 6) Herpes Simplex Virus (" HSV-1") Topical Treatment for Cold Sore Lesions For additional information, please refer to the Company's Management's Discussion and Analysis ("MD&A") available at About Ruvidar®: Ruvidar®(TLD-1433) is a small molecule, able to be activated by light, radiation, sound and/or other drugs, intended for the safe and effective destruction of various cancers, bacteria and viruses. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains Forward-Looking Statements (" FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words " may, " should", " will", " anticipates", " believes", " plans", " expects", " estimate", " potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
